Related Experiment Video
Updated: Jun 17, 2025
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
MiRNA expression as outcome predictor in pediatric AML: systematic evaluation of a new model
Ivan Ellson1, Jordi Martorell-Marugán1,2, Pedro Carmona-Sáez3,4
1GENYO, Centre for Genomics and Oncological Research Pfizer, University of Granada, Andalusian Regional Government, PTS, 18016, Granada, Spain.
Abstract:
Accurately predicting patient outcomes is essential for optimizing treatment and improving outcomes in pediatric acute myeloid leukemia (AML). In recent years, microRNAs have emerged as a promising prognostic marker, with a growing body of evidence supporting their potential predictive value. We systematically reviewed all previous studies that have analyzed the expression of microRNAs as predictors of survival in pediatric AML and found 16 microRNAs and 4 microRNA signatures previously proposed as predictors of survival. We then used a public access cohort of 1414 pediatric AML patients from the TARGET project to develop a new predictive model using penalized lasso Cox regression based on microRNA expression. Here we propose a new score based on a 37-microRNA signature that is associated with AML and is able to predict survival more accurately than previous microRNA-based methods.
Insights
This study introduces a novel 37-microRNA signature for predicting survival in pediatric acute myeloid leukemia (AML). This new score demonstrates superior accuracy compared to existing microRNA-based prognostic methods.
Area of Science:
- Oncology
- Genetics
- Bioinformatics
Background:
- Accurate prediction of patient outcomes is crucial for effective treatment of pediatric acute myeloid leukemia (AML).
- MicroRNAs (miRNAs) are increasingly recognized as potential prognostic markers in various cancers, including pediatric AML.
- Existing miRNA-based survival prediction models for pediatric AML require further refinement.
Purpose of the Study:
- To systematically review previously identified microRNA predictors of survival in pediatric AML.
- To develop and validate a novel, more accurate miRNA-based predictive model for pediatric AML survival.
- To establish a new prognostic score utilizing a comprehensive miRNA signature.
Main Methods:
- Systematic literature review of studies on miRNA expression and survival in pediatric AML.
- Development of a predictive model using penalized lasso Cox regression on miRNA expression data.
- Utilized a large public cohort of 1414 pediatric AML patients from the TARGET project.
Main Results:
- Identified 16 individual microRNAs and 4 microRNA signatures previously proposed as survival predictors.
- Developed a novel predictive score based on a 37-microRNA signature.
- The new 37-miRNA signature demonstrated significantly improved accuracy in predicting survival compared to prior miRNA-based methods.
Conclusions:
- A 37-microRNA signature offers a more accurate method for predicting survival in pediatric AML.
- This novel signature holds potential for optimizing treatment strategies and improving patient outcomes.
- Further validation of this miRNA signature in diverse pediatric AML cohorts is warranted.
